Apart from acting as an agonist for the estrogen receptor and mediating the estrogen receptor expression, Uro-A (10 μM) inhibited the proliferation of endometrial cancer cells at the G2/M phase in a time and dose-dependent manner. The gene discussed is ESR1; the disease is endometrial cancer.